UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners

Adam E. Singer, MD, PhD, discusses factors that inform the choice between IO/IO and IO/TKI regimens for patients with renal cell carcinoma.

John K. Lee, MD, PhD, discusses the EV-302 trial of frontline enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial cancer.

Bartosz Chmielowski, MD, PhD, discusses the rationale for investigating oncolytic viruses in melanoma.

Ritu Salani, MD, MBA, discusses the management of ocular toxicities associated with mirvetuximab soravtansine in ovarian cancer.

Orca-T was retrospectively associated with improved OS in patients with high-risk hematologic malignancies.

Jame Abraham, MD, of Cleveland Clinic, and Rena D. Callahan, MD, of UCLA, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

Aditya Bardia, MD, MPH, FASCO, discusses the efficacy of T-DXd in HER2-low/ultralow metastatic breast cancer by disease progression on prior therapy.

Perioperative vorasidenib or ivosidenib demonstrated sustained clinical benefit in patients with predominantly non-enhancing IDH1-mutant diffuse glioma.

Adam E. Singer, MD, PhD, discusses the safety profiles of immuno-oncology/TKI regimens in first-line renal cell carcinoma.

Adam E. Singer, MD, PhD, discusses currently available combination treatment regimens for the first-line treatment of patients with renal cell carcinoma.

Ian Krop, MD, PhD, and Aditya Bardia, MD, MPH, FASCO, detail how TROP2-directed ADCs have generated excitement in breast cancer and other solid tumors.

Nicholas P. McAndrew, MD, MSCE, discusses a subgroup analysis of the NATALEE trial in HR+/HER2– early breast cancer by prior systemic treatment.

Breast cancer experts highlight early-phase and real-world studies of interest from the 2024 ESMO Congress.

Alexandra Drakaki, MD, PhD, discusses a case study of a patient with refractory metastatic renal cell carcinoma harboring an ALK rearrangement.

Adam Singer, MD, PhD, discusses the lack of clinical benefit for sequential immunotherapy in advanced renal cell carcinoma.

Alexandra Drakaki, MD, PhD, discusses key trials that have shaped the treatment paradigm in non–clear cell renal cell carcinoma.

Alexandra Drakaki, MD, PhD, discusses how the classification of subtypes of non–clear cell renal cell carcinoma has evolved in recent years.

Adam E. Singer, MD, PhD, highlights how cabozantinib and nivolumab treatment compares with other therapies in terms of efficacy and safety in RCC.

Alexandra Drakaki, MD, expands on the need to improve specific classifications in non–clear cell renal cell carcinoma.

Adam E. Singer, MD, PhD, details how he selects between the available TKI/IO combinations and the only dual immunotherapy regimen for patients with RCC.

Alexandra Drakaki, MD, PhD, discusses the potential role of zanzalintinib in advanced non–clear cell renal cell carcinoma.

Yuan Yuan, MD, PhD, discusses the potential shift towards minimizing surgical intervention for lymph node management in breast cancer.

Dana M. Chase, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer.

Experts discuss key takeaways and closing thoughts on antibody-drug conjugates (ADCs) in cancer treatment.

Ronan Kelly, MD, MBA, offers insights on the future for HER2-directed antibody-drug conjugates.

Ronan Kelly, MD, MBA, offers insights on trastuzumab deruxtecan approval as tumor-agnostic HER2-directed therapy.

Ritu Salani, MD, discusses the development of ADCs, the potential role of selinexor, and the use of PARP inhibitors across endometrial cancer subsets.

Ritu Salani, MD, discusses the role of ADCs in ovarian cancer and what the future of the post-IO setting in cervical cancer management may look like.

Key opinion leaders examine promising antibody-drug conjugates (ADCs) in the pharmaceutical development pipeline.

Expert clinicians offer strategic guidance on optimal sequencing of antibody-drug conjugates (ADCs) in treatment protocols.